Literature DB >> 15735699

Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents.

Vladimir L Gabai1, Karine R Budagova, Michael Y Sherman.   

Abstract

The major heat shock protein Hsp72 is expressed at high levels in various types of cancer. Here we attempt to clarify the role of Hsp72 in prostate cancer cells by studying the effects of specific downregulation of this protein using siRNA and antisense RNA approaches. Contrary to previous reports, specific depletion of Hsp72 did not reduce viability of the prostate carcinoma cell lines PC-3 and DU-145. However, even short-term downregulation of Hsp72 in these cells made them more sensitive to hyperthermia, inhibitors of proteasome and Hsp90, and tumor necrosis factor. Interestingly, prolonged downregulation of Hsp72 in PC-3 cells over 3 weeks aggravated these effects, as well as enhanced the sensitivity of cells to oxidative stress, radiation, cis-platinum, vinblastin and taxol. The increased sensitivity to the anticancer agents was due to increased apoptosis, as well as other types of cell death, which resulted in the loss of clonogenic survival. Prolonged downregulation of Hsp72 led to severe suppression of the major survival pathways, ERK and NF-kappaB, which may be responsible for enhanced sensitivity of prostate carcinoma cells to a variety of anticancer treatments, as well as reduction of the cell's capability of forming colonies in soft agar.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15735699     DOI: 10.1038/sj.onc.1208495

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  45 in total

Review 1.  The human HSP70 family of chaperones: where do we stand?

Authors:  Jürgen Radons
Journal:  Cell Stress Chaperones       Date:  2016-02-10       Impact factor: 3.667

Review 2.  Heat shock protein 70 (hsp70) as an emerging drug target.

Authors:  Christopher G Evans; Lyra Chang; Jason E Gestwicki
Journal:  J Med Chem       Date:  2010-06-24       Impact factor: 7.446

Review 3.  RNA interference: ready to silence cancer?

Authors:  Simone Mocellin; Rodolfo Costa; Donato Nitti
Journal:  J Mol Med (Berl)       Date:  2005-11-09       Impact factor: 4.599

Review 4.  [Stress proteins in prostate cancer. Challenge and promise].

Authors:  B A Hadaschik; S W Melchior; R D Sowery; A I So; M E Gleave
Journal:  Urologe A       Date:  2007-05       Impact factor: 0.639

5.  The role of stress proteins in prostate cancer.

Authors:  Alan So; Boris Hadaschik; Richard Sowery; Martin Gleave
Journal:  Curr Genomics       Date:  2007-06       Impact factor: 2.236

6.  Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells.

Authors:  Sara Sannino; Christopher J Guerriero; Amit J Sabnis; Donna Beer Stolz; Callen T Wallace; Peter Wipf; Simon C Watkins; Trever G Bivona; Jeffrey L Brodsky
Journal:  J Cell Sci       Date:  2018-09-05       Impact factor: 5.285

Review 7.  New Opportunities for Targeting the Androgen Receptor in Prostate Cancer.

Authors:  Margaret M Centenera; Luke A Selth; Esmaeil Ebrahimie; Lisa M Butler; Wayne D Tilley
Journal:  Cold Spring Harb Perspect Med       Date:  2018-12-03       Impact factor: 6.915

8.  Hsp72 chaperone function is dispensable for protection against stress-induced apoptosis.

Authors:  Ari M Chow; Rohan Steel; Robin L Anderson
Journal:  Cell Stress Chaperones       Date:  2008-09-26       Impact factor: 3.667

9.  Correlation between clinicopathology and expression of heat shock protein 72 and glycoprotein 96 in human esophageal squamous cell carcinoma.

Authors:  Xiaoping Wang; Qiaoxia Wang; Huanping Lin
Journal:  Clin Dev Immunol       Date:  2010-03-10

Review 10.  Heat shock proteins in animal neoplasms and human tumours--a comparison.

Authors:  Mariarita Romanucci; Tania Bastow; Leonardo Della Salda
Journal:  Cell Stress Chaperones       Date:  2008-03-12       Impact factor: 3.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.